

# ReVeRA—Study of Etripamil in Patients with AF-RVR

## Study Population



Patients presenting to the ED with AF were screened. **87 patients** had AF-RVR with rate  $\geq 110$  bpm



**69 patients** were randomized, 56 received treatment



## Intervention

Efficacy population\* = 49




**24 patients** received etripamil 70 mg nasal spray



**25 patients** received matched placebo

## Efficacy Outcomes



Median time to maximal effect of 13 min and duration of effect up to 150 min.

## Baseline patient demographics



**Median (IQR) age 65** (35–88) years

**61%** men

**39%** women



**75%** had paroxysmal atrial fibrillation

## Most common adverse events

( $\geq 5\%$  of patients)




- Nasal discomfort
- Nasal rhinorrhea
- Lacrimation
- Throat irritation
- Dizziness



These AEs were mild or moderate in intensity  
Few serious AEs occurred, 1 in the etripamil group

## Relief of Symptoms



Etripamil treatment was associated with significant improvement in symptom relief and in treatment satisfaction as measured by the TSQM-9.

\*Efficacy population is comprised of all randomized patients who remained in AF with adequately diagnostic ECG recordings for at least 60 min post drug